Marshall Wace LLP raised its position in shares of BioPlus Acquisition Corp. (NASDAQ:BIOS – Get Rating) by 31.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 502,350 shares of the company’s stock after acquiring an additional 120,000 shares during the quarter. Marshall Wace LLP owned approximately 1.71% of BioPlus Acquisition worth $5,049,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of BIOS. First Trust Capital Management L.P. boosted its position in shares of BioPlus Acquisition by 50.0% in the 3rd quarter. First Trust Capital Management L.P. now owns 150,000 shares of the company’s stock worth $1,507,000 after purchasing an additional 50,000 shares in the last quarter. Cantor Fitzgerald L. P. lifted its holdings in shares of BioPlus Acquisition by 6.3% during the 3rd quarter. Cantor Fitzgerald L. P. now owns 850,000 shares of the company’s stock valued at $8,542,000 after buying an additional 50,000 shares during the period. Shaolin Capital Management LLC lifted its holdings in shares of BioPlus Acquisition by 83.6% during the 3rd quarter. Shaolin Capital Management LLC now owns 379,302 shares of the company’s stock valued at $3,812,000 after buying an additional 172,740 shares during the period. Aristeia Capital LLC bought a new position in shares of BioPlus Acquisition during the 3rd quarter valued at $2,334,000. Finally, Wolverine Asset Management LLC bought a new position in shares of BioPlus Acquisition during the 3rd quarter valued at $404,000. 72.81% of the stock is owned by institutional investors.
BioPlus Acquisition Price Performance
NASDAQ BIOS opened at $10.40 on Tuesday. BioPlus Acquisition Corp. has a 1-year low of $9.85 and a 1-year high of $10.43. The business’s fifty day moving average price is $10.33 and its 200-day moving average price is $10.19.
BioPlus Acquisition Profile
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
- Get a free copy of the StockNews.com research report on BioPlus Acquisition (BIOS)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioPlus Acquisition Corp. (NASDAQ:BIOS – Get Rating).
Receive News & Ratings for BioPlus Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPlus Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.